Aprogen raises Aprogen Biologics stake to 72.84% from 56.59% in disclosure

• Aprogen raised its stake in Aprogen Biologics to 25,300,813 securities, lifting ownership to 75.59% as of Oct. 2.
• Common shares held increased to 21,908,683 from 9,202,202, raising the equity stake to 72.84%.
• The change was driven by a paid-in capital increase on Sept. 23 at KRW 1,574 per share.
• Convertible bond holdings rose to 3,392,130 from 3,244,646 following an exercise price adjustment on Sept. 24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002000650), on October 02, 2026, and is solely responsible for the information contained therein.